Synthetic biology (synbio) treats biology as a designable, programmable technology platform. Rather than merely studying living systems, synthetic biologists engineer them — designing DNA sequences, metabolic pathways, and cellular behaviors from scratch or modifying existing organisms to produce medicines, materials, fuels, and foods. The field draws on molecular biology, genetic engineering, computer science, and engineering to create biological systems with predictable, useful functions.
The synbio industry has grown rapidly, attracting tens of billions of dollars in investment. Ginkgo Bioworks, which went public in 2021, operates as a "cell programming" platform, engineering microorganisms for clients across pharmaceuticals, agriculture, and industrial chemicals. Amyris (now part of other entities after financial restructuring) pioneered the production of artemisinin (an antimalarial drug) and squalane (a cosmetics ingredient) via engineered yeast. Twist Bioscience manufactures synthetic DNA at scale, providing the raw building blocks for the entire synbio ecosystem.
The applications span nearly every industry. Synbio-produced proteins are replacing animal-derived ingredients in food (Impossible Foods) and materials (Bolt Threads' spider silk). Engineered microbes produce biofuels, fragrances, and industrial chemicals. In medicine, synthetic biology enables cell and gene therapies, mRNA vaccine production, and biosensor diagnostics. As DNA synthesis costs continue to fall and design tools improve, synthetic biology is positioned to become a foundational technology platform rivaling software in its breadth of application. For deeper coverage, see SynBioIntel.